CRISPR Therapeutics (NASDAQ: CRSP) has hired Tony Ho to serve as the company’s executive vice president and head of research and development. Switzerland-based CRISPR Therapeutics, which maintains its R&D operations in Cambridge, MA, is developing therapies based on the CRISPR gene-editing technology. Ho comes to the company from AstraZeneca (NYSE: AZN), where he was senior vice president and head of oncology integration and innovation.
Sponsored · Whitepaper
Knowing the volume of procedures and growth trends by site of care can allow you to understand the market demand for your product
IBM Watson
Sponsored · Whitepaper
How a patient-centric, technology-driven approach can broaden access to research and reach patients regardless of geography, ethnicity, sex, or gender
PRA Health Sciences
Sponsored · Webinar
Provide an in vitro drug-induced proarrhythmia assessment & strengthen pharmacological safety profiles of drug candidates
Eurofins DiscoverX
